Latest Articles
Real-word evidence on the effectiveness of the Endo-App in reducing endometriosis-related complaints: a retrospective analysis.
Randomized controlled clinical trials have shown that symptoms of chronic pain conditions, such as endometriosis, can be improved with the use of specialized health apps. In the current study, real-world …
Published: July 27, 2026, midnight
Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis.
Mineralocorticoid receptor antagonists, spironolactone, eplerenone, and finerenone, are cornerstone therapies in cardiovascular and renal diseases. While their efficacy is established, a systematic, head-to-head comparison of their post-marketing safety profiles based …
Published: June 23, 2026, midnight
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence.
Published: April 16, 2026, midnight
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence - OncLive
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence OncLive
Published: Dec. 5, 2025, 1 p.m.
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).
Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …
Published: Jan. 8, 2025, midnight
Link copied to clipboard!